How to buy GoodRx stock | $50.14

GoodRx is now publicly available to trade. The stock opened at $46, nearly 40% above it's IPO price of $33.

Launched in 2011, GoodRx allows customers to compare prescription drug prices. It's since become a household name, which may be one of the reasons that the stock has been getting so much buzz. If you're planning to invest, here's how you can buy in.

How to buy shares in GoodRx

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for GoodRx. Find the stock by name or ticker symbol: GDRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until GoodRx reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$50.14, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of GoodRx, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of GoodRx. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

GoodRx share price

Use our graph to track the performance of GDRX stocks over time.

GoodRx shares at a glance

• Key figures

Information last updated 2020-10-19.

Latest market close	USD$50.14
52-week range	USD$45.5 - USD$64.219
50-day moving average	USD$52.9497
200-day moving average	USD$52.9497
Wall St. target price	N/A
PE ratio	217.3396
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy GoodRx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy GoodRx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of GoodRx Holdings, Inc. by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GoodRx price performance over time

Historical closes compared with the close of $50.14 from 2020-10-19

1 week (2021-01-15)	16.88%
1 month (2020-12-23)	5.36%
3 months (2020-10-23)	-4.50%
6 months (2020-07-19)	N/A

1 year (2020-01-19)	N/A
2 years (2019-01-19)	N/A
3 years (2018-01-19)	N/A
5 years (2016-01-19)	N/A

Is GoodRx under- or over-valued?

Valuing GoodRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GoodRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GoodRx's P/E ratio

GoodRx's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 217x. In other words, GoodRx shares trade at around 217x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, GoodRx's P/E ratio is best considered in relation to those of others within the health information services industry or those of similar companies.

• Teva Pharmaceutical Industries (TEVA.US): 872.00
• Humana (HUM.US): 12.97

GoodRx's EBITDA

GoodRx's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$176.4 million.

The EBITDA is a measure of a GoodRx's overall financial performance and is widely used to measure a its profitability.

To put GoodRx's EBITDA into context you can compare it against that of similar companies.

• Teva Pharmaceutical Industries (TEVA.US): USD$4.6 billion
• Teladoc Health (TDOC.US): USD$18.8 million
• Humana (HUM.US): USD$6 billion

GoodRx financials

Revenue TTM	USD$471.7 million
Operating margin TTM	34.23%
Gross profit TTM	USD$374.2 million
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	18.98%
Book value	N/A
Market capitalisation	USD$19.9 billion

TTM: trailing 12 months

Shorting GoodRx shares

There are currently 1.9 million GoodRx shares held short by investors – that's known as GoodRx's "short interest". This figure is up from 0 last month.

There are a few different ways that this level of interest in shorting GoodRx shares can be evaluated.

GoodRx's "short interest ratio" (SIR)

GoodRx's "short interest ratio" (SIR) is the quantity of GoodRx shares currently shorted divided by the average quantity of GoodRx shares traded daily (recently around 8.7 million). GoodRx's SIR currently stands at 0.22. In other words for every 100,000 GoodRx shares traded daily on the market, roughly 220 shares are currently held short.

To gain some more context, you can compare GoodRx's short interest ratio against those of similar companies.

• Teva Pharmaceutical Industries (TEVA.US): 4.45
• Teladoc Health (TDOC.US): 5.23
• Humana (HUM.US): 1.75

However GoodRx's short interest can also be evaluated against the total number of GoodRx shares, or, against the total number of tradable GoodRx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GoodRx's short interest could be expressed as 0% of the outstanding shares (for every 100,000 GoodRx shares in existence, roughly 0 shares are currently held short) or 0.0449% of the tradable shares (for every 100,000 tradable GoodRx shares, roughly 45 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against GoodRx.

Find out more about how you can short GoodRx stock.

GoodRx share dividends

We're not expecting GoodRx to pay a dividend over the next 12 months.

You may also wish to consider:

• Humana (HUM.US) (0.62% forward annual dividend yield)

GoodRx overview

GoodRx Holdings, Inc. is a holding company. The company, through its subsidiaries, owns and operates a prescription drug price comparison platform using data from local and mail-order pharmacies in the United States. It also provides pharmacy coupons to customers. The company offers generic and brand name pricing; alerts clients on manufacturer co-pay cards, pharmacy discounts, and state discount programs; and provides tips on slashing drug prices. It provides prices of drugs in areas of alcohol dependence, allergies, cold, Alzheimer's disease, angina, antibiotics, anticoagulant, antiviral, antiplatelet, anxiety, arrhythmia, arrhythmia, asthma, bipolar disorder, birth control, cancer, cerebral hemorrhage, cholesterol, COPD, depression, dermatology, diabetes, ear, enlarged prostate, epilepsy, eye, fertility, fibromyalgia, flu, gastrointestinal, heart failure, hypertension, hypotension, immune system, insomnia, medical supplies, men's health, mental health, migraine, myasthenia gravis, nausea, nervous system, obesity, obsessive-compulsive disorder, opioid dependence, pain relief, arthritis, panic disorder, Parkinson's disease, PMDD, restless leg syndrome, schizophrenia, seizure, sleep aids, smoking and addiction, smoking cessation, thyroid drugs, Tourette syndrome, trazodone, urology, vaccines, and women's health. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.

Frequently asked questions

• How many people work for GoodRx?

  Latest data suggests 338 work at GoodRx.

• When does the fiscal year end for GoodRx?

  GoodRx's fiscal year ends in December.

• Where is GoodRx based?

  GoodRx's address is: 233 Wilshire Boulevard, Santa Monica, CA, United States, 90401